Embecta (EMBC) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic achievements and transformation

• Completed separation from former parent, establishing independent operations, ERP, and distribution networks with no customer disruption.

• Achieved or exceeded financial targets, with adjusted EBITDA margin at 31.4% for FY2024 and revenue CAGR of 1.3% through fiscal 2024.

• Successfully transferred Suzhou, China facility, implemented global back-office and customer support systems, and published ESG strategy report.

• Named exclusive or dual preferred brand with three top Medicare Part D players and secured additional contracts.

• Presented transformation strategy and business update for 2025 at the 43rd Annual JP Morgan Healthcare Conference.

Core business performance and market trends

• Pen needles and safety products, comprising 86% of revenue, grew at 2.3% and 2.9% CAGR respectively over five years; pen needles showed 2.6% adjusted constant currency revenue growth in FY2024.

• Syringe sales declined by 6.3%, reflecting a shift from vials to pens and broader market changes.

• Brand transition project underway, starting in the U.S. and Canada in 2025, with global completion expected in a few years.

• Emerging markets expected to drive disproportionate future growth due to rising diabetes prevalence and economic factors.

• U.S. market faces pricing challenges in 2025 due to contract renewals and lower inflation.

Growth strategy and portfolio expansion

• Focus on leveraging global commercial and distribution strengths, with over 600 commercial employees and 16 distribution centers, to add new products and expand the portfolio.

• Exploring opportunities to manufacture or distribute additional medical products, utilizing automated facilities and operational expertise.

• Actively engaging with over 10 generic GLP-1 entrants for co-packaging pen needles, targeting growth from GLP-1 market expansion.

• No significant capital investment needed to support incremental GLP-1-related volume.

• Expansion will be driven by external distribution agreements and partnerships to maximize portfolio reach.